Search

Your search keyword '"Lanzetta, Paolo"' showing total 805 results

Search Constraints

Start Over You searched for: Author "Lanzetta, Paolo" Remove constraint Author: "Lanzetta, Paolo"
805 results on '"Lanzetta, Paolo"'

Search Results

2. Real-world practice patterns of eplerenone use for central serous chorioretinopathy.

6. TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2

7. Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials

8. Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial

9. Vitrectomized vs non-vitrectomized eyes in DEX implant treatment for DMO—Is there any difference? the VITDEX study

10. Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial

11. Update on coronavirus disease 2019: Ophthalmic Manifestations and Adverse Reactions to Vaccination

12. Intraocular pressure (IOP) after intravitreal dexamethasone implant (Ozurdex) amongst different geographic populations-GEODEX-IOP study.

13. Intraocular pressure (IOP) after intravitreal dexamethasone implant (Ozurdex) amongst different geographic populations—GEODEX-IOP study

15. Current status and practical considerations of artificial intelligence use in screening and diagnosing retinal diseases: Vision Academy retinal expert consensus

16. The impact of artificial intelligence on retinal disease management: Vision Academy retinal expert consensus

18. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials

19. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials

23. TENAYA and LUCERNE

27. RWC Update: Different Surgical Techniques for Macular Hole Associated With Retinal Detachment; Diabetic Macular Edema – How Do You Treat Patients With Good Visual Acuity?; Benign Familial Fleck Retina.

28. Stem cell therapy in retinal diseases: current evidence.

29. Macular Holes

32. Faricimab Treat-and-Extend for Diabetic Macular Edema

33. Towards a Long-Read Sequencing Approach for the Molecular Diagnosis of RPGRORF15 Genetic Variants

34. Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial

36. Current role of intravitreal injections in Irvine Gass syndrome-CRIIG study

37. Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study

41. The Present and Future of Optic Pathway Glioma Therapy

45. Global causes of blindness and distance vision impairment 1990–2020: a systematic review and meta-analysis

48. Validation of Esaso Classification of Diabetic Maculopathy

49. Submakuläre Blutungen bei neovaskulärer altersbedingter Makuladegeneration: Eine Meta-Analyse und Meta-Regression über den Einsatz von tPA und Anti-VEGF

Catalog

Books, media, physical & digital resources